As of May 31, 2025, Adamas Pharmaceuticals Inc (ADMS) reports a Current Ratio of 3.20.
Current Ratio assesses a company's ability to pay short-term debts by comparing liquid assets to liabilities, with higher ratios signaling better financial health.
Historical Trend of Adamas Pharmaceuticals Inc's Current Ratio
Over recent years, Adamas Pharmaceuticals Inc's Current Ratio has shown significant volatility. The table below summarizes the historical values:
| Date | Current Ratio |
|---|---|
| 2020-12-31 | 3.20 |
| 2019-12-31 | 5.59 |
| 2018-12-31 | 9.40 |
| 2017-12-31 | 10.80 |
| 2016-12-31 | 12.06 |
This gradual decrease highlights how Adamas Pharmaceuticals Inc manages its short-term assets and liabilities over time.
Comparing Adamas Pharmaceuticals Inc's Current Ratio to Peers
To better understand Adamas Pharmaceuticals Inc's position, it's useful to compare its Current Ratio against industry peers. Below are selected comparisons:
| Company | Current Ratio |
|---|---|
| Adamas Pharmaceuticals Inc (ADMS) | 3.20 |
| LogicBio Therapeutics Inc (LOGC) | 31.20 |
| Heat Biologics Inc (HTBX) | 21.04 |
| IsoRay Inc (ISR) | 19.86 |
| Savara Inc (SVRA) | 13.73 |
| Corbus Pharmaceuticals Holdings Inc (CRBP) | 12.94 |
Compared to its competitors, Adamas Pharmaceuticals Inc's Current Ratio is about average compared to peers, reflecting balanced short-term asset management.